Pfizer (NYSE: PFE ) refuses to take no for an answer in its pursuit of the next great pharma mega merger.
Its target, AstraZeneca (NYSE: AZN ) , recently rebuffed a higher bid, $106 billion in a more attractive cash/stock mix -- however the deal was still not attractive enough for the British pharma's management. Pfizer has also worked to hard to keep the U.K. government from standing in the way of the deal, agreeing to keep jobs on that side of the Atlantic.
In this episode of Market Check-Up, the Motley Fool's health-care focused investing show, analysts David Williamson and Michael Douglass discuss the details of the deal and why AstraZeneca turned it down, and why Pfizer isn't going silently into the night.
Investors should watch the video below and then stay tuned for The Fool's analysis of Pfizer's quarterly results on Monday.
Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!